Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

European Innovation Council · Running

TUMAGNOSTIC A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach

Coordinator
Convert Pharmaceuticals, Belgium
Runs
1 January 2024 to 31 December 2025
Status
Running
EU funding
€2.5m
Total cost
€3.5m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190158311

What the project is doing

In the project's own words, from its summary on CORDIS.

TUMAGOSTIC will advance the development of CP-506, a next-generation Hypoxia Activated Prodrug (HAP) for the treatment of hypoxic tumours, representing over 50% of all solid tumours. CP-506 overcomes the limitations of previous HAP development attempts and can provide more targeted treatment compared with alternatives such as chemo-immunotherapy combination and PARPi. Our approach, combining CP-506 with improved patient targeting based on two AI-driven biomarkers (tumour hypoxia and Homologous Recombination Defect), has high potential to increase the effectiveness of standard of care therapies such as immunotherapy (IO) in combination therapy (prodrug-IO) and improve patients’ progression free survival and quality of life in several cancer types.

We aim to advance CP-506 towards commercialization by carrying out a phase I-IIa clinical trial and corresponding business development activities, paving the way for a licensing agreement with the potential to exceed €450M.

Topics

Who is involved

OrganisationCityCountryRole
Convert PharmaceuticalsLiegeBelgiumCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI